NO985695L - Formulation and procedure for treating congestive heart attack - Google Patents
Formulation and procedure for treating congestive heart attackInfo
- Publication number
- NO985695L NO985695L NO985695A NO985695A NO985695L NO 985695 L NO985695 L NO 985695L NO 985695 A NO985695 A NO 985695A NO 985695 A NO985695 A NO 985695A NO 985695 L NO985695 L NO 985695L
- Authority
- NO
- Norway
- Prior art keywords
- congestive heart
- formulation
- heart attack
- procedure
- treating congestive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Foreliggende oppfinnelse skaffer tilveie en fremgangsmåte for å behandle kongestiv hjerteinfarkt som består i å administrere en virksom mengde av 4-klor-5-(imidazolin-2- ylamino)-6-metoksy-2-metylpyrimidin i en oral eller implantert formulering med ikke umiddelbar frigjøring og formuleringer med ikke umiddelbar frigjøring.The present invention provides a method of treating congestive heart attack consisting of administering an effective amount of 4-chloro-5- (imidazolin-2-ylamino) -6-methoxy-2-methylpyrimidine in an oral or implanted formulation with non-immediate release and non-immediate release formulations.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65946396A | 1996-06-06 | 1996-06-06 | |
PCT/US1997/009914 WO1997046241A1 (en) | 1996-06-06 | 1997-06-05 | Formulation and method for treating congestive heart failure |
Publications (2)
Publication Number | Publication Date |
---|---|
NO985695D0 NO985695D0 (en) | 1998-12-04 |
NO985695L true NO985695L (en) | 1999-02-04 |
Family
ID=24645503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO985695A NO985695L (en) | 1996-06-06 | 1998-12-04 | Formulation and procedure for treating congestive heart attack |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0914128A1 (en) |
JP (1) | JP2000511906A (en) |
KR (1) | KR20000016406A (en) |
CN (1) | CN1226166A (en) |
AU (1) | AU3233197A (en) |
BR (1) | BR9709546A (en) |
CA (1) | CA2256720A1 (en) |
CZ (1) | CZ397698A3 (en) |
EA (1) | EA199900006A1 (en) |
HU (1) | HUP0003885A2 (en) |
IL (1) | IL126966A0 (en) |
NO (1) | NO985695L (en) |
PL (1) | PL330637A1 (en) |
TR (1) | TR199802496T2 (en) |
WO (1) | WO1997046241A1 (en) |
YU (1) | YU55998A (en) |
ZA (1) | ZA974978B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19815411A1 (en) * | 1998-04-06 | 1999-10-07 | Solvay Pharm Gmbh | Thermogenesis stimulant comprising moxonidine, useful e.g. for treating hypothermia or promoting weight loss, having no cardiac stimulant side effects |
AU2727400A (en) * | 1999-01-29 | 2000-08-18 | Eli Lilly And Company | Moxonidine salts |
UA67822C2 (en) * | 1999-02-01 | 2004-07-15 | Солвей Фармас'Ютікалс Гмбх | Use of moxonidine for treatment of myocardial infarction damages of myocardium, method for producing pharmaceutical composition |
ATE487712T1 (en) * | 2006-08-31 | 2010-11-15 | Chemagis Ltd | USE OF MONOXIDINE SALTS TO PURIFY MONOXIDINE |
KR100812287B1 (en) * | 2007-01-03 | 2008-03-13 | 주식회사 챠콜코리아 | Shade for a traffic signal lamp having reflective layer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4323570A (en) * | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
DE3617158C2 (en) * | 1986-05-22 | 1994-10-06 | Lohmann Therapie Syst Lts | Transdermal drug |
DE3729299A1 (en) * | 1987-09-02 | 1989-03-23 | Beiersdorf Ag | TRANSDERMAL THERAPEUTIC SYSTEM |
DE3904795C2 (en) * | 1989-02-17 | 2000-10-12 | Lilly Pharma Produktion Gmbh & | Pharmaceutical preparation and its use |
DE4325491A1 (en) * | 1993-07-29 | 1995-02-02 | Boehringer Ingelheim Kg | Use of centrally acting alpha-2 agonists to inhibit post-aggression metabolism |
DE4423177A1 (en) * | 1994-07-01 | 1996-01-04 | Kali Chemie Pharma Gmbh | Antihyperglycemic drugs |
CA2182851A1 (en) * | 1995-08-15 | 1997-02-16 | August Masaru Watanabe | Method for treating substance abuse withdrawal |
-
1997
- 1997-06-05 HU HU0003885A patent/HUP0003885A2/en unknown
- 1997-06-05 CA CA002256720A patent/CA2256720A1/en not_active Abandoned
- 1997-06-05 AU AU32331/97A patent/AU3233197A/en not_active Abandoned
- 1997-06-05 ZA ZA974978A patent/ZA974978B/en unknown
- 1997-06-05 BR BR9709546A patent/BR9709546A/en not_active Application Discontinuation
- 1997-06-05 WO PCT/US1997/009914 patent/WO1997046241A1/en not_active Application Discontinuation
- 1997-06-05 IL IL12696697A patent/IL126966A0/en unknown
- 1997-06-05 KR KR1019980709980A patent/KR20000016406A/en not_active Application Discontinuation
- 1997-06-05 JP JP10500901A patent/JP2000511906A/en active Pending
- 1997-06-05 TR TR1998/02496T patent/TR199802496T2/en unknown
- 1997-06-05 PL PL97330637A patent/PL330637A1/en unknown
- 1997-06-05 EP EP97928011A patent/EP0914128A1/en not_active Withdrawn
- 1997-06-05 CZ CZ983976A patent/CZ397698A3/en unknown
- 1997-06-05 CN CN97196854A patent/CN1226166A/en active Pending
-
1998
- 1998-12-04 NO NO985695A patent/NO985695L/en not_active Application Discontinuation
- 1998-12-04 YU YU55998A patent/YU55998A/en unknown
-
1999
- 1999-01-06 EA EA199900006A patent/EA199900006A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TR199802496T2 (en) | 1999-02-22 |
KR20000016406A (en) | 2000-03-25 |
NO985695D0 (en) | 1998-12-04 |
YU55998A (en) | 1999-11-22 |
AU3233197A (en) | 1998-01-05 |
BR9709546A (en) | 1999-08-10 |
WO1997046241A1 (en) | 1997-12-11 |
PL330637A1 (en) | 1999-05-24 |
HUP0003885A2 (en) | 2001-04-28 |
EA199900006A1 (en) | 1999-06-24 |
IL126966A0 (en) | 1999-09-22 |
EP0914128A1 (en) | 1999-05-12 |
CN1226166A (en) | 1999-08-18 |
CZ397698A3 (en) | 1999-05-12 |
ZA974978B (en) | 1998-12-07 |
CA2256720A1 (en) | 1997-12-11 |
JP2000511906A (en) | 2000-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO993979L (en) | Procedures to prevent and delay the onset of Alzheimer's disease and its composition | |
TR199801315T2 (en) | Use of a ppar-alpha and ppar-gamma antagonist for the treatment of syndrome X. | |
NO20012774D0 (en) | Preparation and method using essential plant oils | |
ZA88798B (en) | Dental anti-plaque and anti-caries agent | |
HU9603042D0 (en) | Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration | |
IL187254A (en) | ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB | |
DE69814394D1 (en) | USE OF LEVOBUPIVACAIN | |
MX9706957A (en) | Composition containing amlodipine, or a salt or felodipine and anace inhibitor. | |
HK1047707A1 (en) | Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence | |
TR199901003T2 (en) | Composition containing loratadine and a decongestant for the treatment of asthma. | |
DE59308848D1 (en) | USE OF URODILATIN IN LUNG AND BRONCHIAL DISEASES | |
FR2731907B1 (en) | DEPIGMENTING DERMATOLOGICAL AND / OR COSMETIC COMPOSITION AND USE IN A COSMETIC METHOD | |
SE9603725D0 (en) | New teatment | |
MX9703944A (en) | Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis. | |
NO984760L (en) | Use of an osmolyte in the treatment of effects caused by an infection, inflammation or immune dysfunction | |
NO985695L (en) | Formulation and procedure for treating congestive heart attack | |
EP0744176A3 (en) | Methods for inhibiting bone loss | |
UA50761C2 (en) | Method for prevention and/or treatment of heart failure and ventricular dysfunction in warm-blooded animals, pharmaceutical formulation | |
DE69924483D1 (en) | COMBINATION THERAPY FOR THE TREATMENT OF TUMORS | |
AU3439799A (en) | Immunization against and treatment for infection by (h.pylori) | |
WO1999031136A3 (en) | Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells | |
EP0743068A3 (en) | Composition for inhibiting bone loss containing vanadyl sulfate | |
HUP0104498A2 (en) | Wood preservative formulations | |
AU6648200A (en) | Method and composition for preventing or treating adverse physiological effects associated with cardiac disease | |
HUP9904578A2 (en) | Use of xanomeline for the preparation of pharmaceutical compositions treating bipolar disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |